Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs STE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 4 – 2 STE Matrix Metrics: DXCM 6 – 4 STE

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas STE carries 42.6/100 (HOLD) at $255.76 (23.1x Forward P/E, 19.2% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile STE trades in a Markup technical trend (SURGE options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs STE
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
STE NYSE
STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$255.76
+0.39% 1D
Market Cap $24.7B
TTM Revenue $6.17B
Forward P/E 23.1x
Beta / 30D Vol 0.18β · 35% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $247.16 · SMA50: $227.43

6-Pillar Scorecard Institutional Category Breakdown (DXCM 4 – 2 STE)

Columns: Metric · DXCM · STE
1. Valuation Multiples STE
Forward P/E 25.3x 23.1x
Trailing P/E 31.6x 30.2x
PEG Ratio 1.30x 2.53x
EV / Revenue 5.9x 4.3x
2. Growth & Scale DXCM
Revenue Growth (YoY) +11.2% +8.8%
Earnings Growth (YoY) +2.6% +12.9%
TTM Revenue (USD) $5.10B $6.17B
Market Cap $29.9B $24.7B
3. Profitability & Quality DXCM
Gross Margin 63.4% 44.3%
Operating Margin 24.0% 19.2%
Net Profit Margin 19.4% 13.4%
Return on Equity (ROE) 37.7% 11.6%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $937M
Cash Flow Margin 33.9% 15.2%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $1.52B Net Debt (0.28x D/E)
Dividend Yield None (0.00%) 0.99%
5. Options & Positioning STE
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 63.0% (15th %ile) 30.0% (7th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) 4.50x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DXCM
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 25.1% of Rev ($1.55B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (6) vs STE (4)
Institutional Metric DXCM STE Criterion Row Edge
Market Capitalization
Scale
$29.9B $24.7B Larger Scale DXCM
Trailing P/E Ratio
Valuation
31.6x 30.2x Lower Multiple STE
Forward P/E Ratio
Valuation
25.3x 23.1x Lower Multiple STE
Revenue Growth (YoY)
Growth
+11.2% +8.8% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 19.2% Higher Margin DXCM
Net Profit Margin
Profitability
19.4% 13.4% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 11.6% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 82% ($195–$269) Stronger Trend STE
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.18β · 35% Vol Lower Realized Risk STE
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $6.17B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 44.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 2.53x PEG · 4.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $937M ($1.52B Net Debt (0.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STE +8.86 pp
DXCM: +1.28% · STE: +10.14%
3M Horizon STE +20.41 pp
DXCM: -12.89% · STE: +7.52%
6M Horizon STE +8.09 pp
DXCM: +10.01% · STE: +18.1%
1Y Horizon DXCM +32.39 pp
DXCM: +32.8% · STE: +0.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue STE Revenue DXCM Op. Margin STE Op. Margin Margin Leader
FY2019 $1.48B $2.78B 9.6% 14.8% STE
FY2020 $1.93B $3.03B 15.5% 17.7% STE
FY2021 $2.45B $3.11B 10.9% 17.6% STE
FY2022 $2.91B $4.22B 13.4% 11.3% DXCM
FY2023 $3.62B $4.54B 16.5% 17.4% STE
FY2024 $4.03B $5.14B 14.9% 16.3% STE
FY2025 $4.66B $5.46B 19.6% 15.9% DXCM
FY2026 N/A $5.94B N/A 18.6% STE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STE SURGE
5d in phase · OBV DISTRIBUTION
Current IV 30.0%
IV Percentile 7th %ile
Put/Call OI Skew 4.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact STE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,161)

Compare $8,161 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 39.6% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $85 / $75 Bear Put Spread

Buy 1x $85P · Sell 1x $75P · 31d

Net Entry $380 Debit
T+5d @ -5% Drop +$186 (+49%)
Max Risk / Buffer $380 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
STE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $24.7B market capitalization and 19.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($1.55B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs STE Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas STE carries 42.6/100 (HOLD) at $255.76 (23.1x Forward P/E, 19.2% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile STE trades in a Markup technical trend (SURGE options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with STE at +8.8% YoY revenue growth and +12.9% YoY earnings growth on $6.17B TTM revenue (44.3% gross margin, 19.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), DXCM cumulative revenue shifted +214.9% while STE shifted +113.7%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($1.55B) (0 disclosures) for STE.

STE screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas STE trades at 23.1x Forward P/E, 30.2x Trailing P/E, 2.53x PEG, and 4.3x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus STE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, STE carries 30.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 4.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.18β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.